CRIS Current Research Information System

BARBARA, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.168
AS - Asia 1.903
EU - Europa 797
SA - Sud America 198
Continente sconosciuto - Info sul continente non disponibili 112
AF - Africa 78
Totale 5.256
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.095
SG - Singapore 621
VN - Vietnam 434
CN - Cina 385
HK - Hong Kong 213
BR - Brasile 157
SE - Svezia 139
IT - Italia 116
DE - Germania 98
NL - Olanda 97
RU - Federazione Russa 64
GB - Regno Unito 59
IE - Irlanda 59
FR - Francia 49
JP - Giappone 43
IN - India 42
CA - Canada 41
KR - Corea 39
BG - Bulgaria 38
CI - Costa d'Avorio 23
SC - Seychelles 23
AR - Argentina 21
PH - Filippine 20
FI - Finlandia 19
MX - Messico 17
BD - Bangladesh 14
CH - Svizzera 14
ID - Indonesia 13
UA - Ucraina 12
TG - Togo 11
IQ - Iraq 10
JO - Giordania 10
ZA - Sudafrica 10
TH - Thailandia 9
AT - Austria 8
ES - Italia 7
IR - Iran 7
PK - Pakistan 7
PL - Polonia 7
TR - Turchia 7
BH - Bahrain 6
CO - Colombia 6
TW - Taiwan 6
EC - Ecuador 5
PY - Paraguay 4
CL - Cile 3
CR - Costa Rica 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
BE - Belgio 2
EE - Estonia 2
ET - Etiopia 2
HN - Honduras 2
KE - Kenya 2
KZ - Kazakistan 2
LT - Lituania 2
MY - Malesia 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
RO - Romania 2
AZ - Azerbaigian 1
BF - Burkina Faso 1
BY - Bielorussia 1
CU - Cuba 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GP - Guadalupe 1
GT - Guatemala 1
IS - Islanda 1
JM - Giamaica 1
MU - Mauritius 1
NP - Nepal 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
VG - Isole Vergini Britanniche 1
Totale 5.144
Salva come PNG Salva come JPEG
Città #
Singapore 354
San Jose 273
Santa Clara 236
Hong Kong 202
Ashburn 187
Council Bluffs 149
Ho Chi Minh City 117
Chandler 114
Hanoi 97
Boardman 89
Beijing 84
Princeton 62
Dublin 58
Los Angeles 49
Southend 38
New York 37
Sofia 34
Hefei 29
Tokyo 29
Seoul 28
Chicago 26
Lauterbourg 26
São Paulo 26
Abidjan 23
Berlin 22
Buffalo 19
Dallas 18
Helsinki 18
Redondo Beach 16
Bologna 15
Guangzhou 15
Milan 15
Phoenix 15
Bern 14
Da Nang 14
Frankfurt am Main 13
Haiphong 13
Falkenstein 12
Houston 12
Montreal 12
Columbus 11
Lomé 11
Shanghai 11
Amman 10
Amsterdam 10
Denver 10
Boston 9
Mexico City 9
Nuremberg 9
Hangzhou 8
Mumbai 8
Salt Lake City 8
Yubileyny 8
Turin 7
Warsaw 7
Washington 7
Bengaluru 6
Bowie 6
Fairfield 6
Kyiv 6
Long Xuyen 6
Manila 6
Naples 6
Rome 6
Bangkok 5
Belo Horizonte 5
Biên Hòa 5
Campinas 5
Fuzhou 5
Hải Dương 5
London 5
Manama 5
Manaus 5
Miami 5
Orem 5
Queens 5
Quận Bình Thạnh 5
Reggio Emilia 5
San Francisco 5
Shenzhen 5
Xi'an 5
Abbeville 4
Chennai 4
Hưng Yên 4
Kunming 4
Munich 4
Olalla 4
Ottawa 4
Rio de Janeiro 4
Salvador 4
Seattle 4
Shijiazhuang 4
Taiyuan 4
The Dalles 4
Thái Nguyên 4
Tianjin 4
Toronto 4
Tân Tiến 4
Vũng Tàu 4
Wuhan 4
Totale 2.962
Salva come PNG Salva come JPEG
Nome #
5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema 293
5-Aminosalicylic acid suppositories in the management of ulcerative colitis 268
Optimum dosage of 5-Aminosalicylic acid as rectal enemas in patients with active ulcerative colitis 142
Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients 128
Bioavailability of single and multiple doses of a new oral formulation of 5‐ASA in patients with inflammatory bowel disease and healthy volunteers 123
Changes in splanchnic hemodynamics in inflammatory bowel disease non-invasive assessment by doppler ultrasound flowmetry 119
Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission 116
Interleukin 1 in ulcerative colitis 116
5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? 113
Role of rectal formulations: Enemas 113
Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease 112
Scavenger effect of sulphasalazine (SASP), 5-aminosalicylic acid (5-ASA), and olsalazine (OAZ) (I) 112
Bronchopulmonary involvement in ulcerative colitis 108
Cost-effectiveness analysis of the preparation of colonoscopy. Comparison between a PEG-electrolyte solution and a standard preparation 105
Short report: zinc sulphate supplementation corrects abnormal erythrocyte membrane long‐chain fatty acid composition in patients with Crohn's disease 104
Macrophage subpopulations in pouchitis 104
Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation 103
Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis 102
Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation - A double-blind placebo controlled trial 101
Mucosal concentrations of interleukin-1β, interleukin-6, interleukin-8, and tumor necrosis factor-α in pelvic ileal pouches 99
Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis 99
Pentasa in maintenance treatment of ulcerative colitis 97
Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration 95
Requirements for the use of intestinal action antibiotics in the treatment of ulcerative colitis 94
Rifaximin suspension for the eradication of helicobacter pylori 88
Helicobacter pylori in Patients with Gastric and Nongastric Cancer 83
Gastric retention of sucralfate gel and suspension in upper gastrointestinal diseases 69
A clinical study of gastric emptying and bioadhesitivity of two forms of sucralfate 68
Rifaximin suspension for the eradication of helicobacter pylori 67
Familial adenomatous polyposis and inflammatory bowel disease associated in two kindreds 67
Gastric retention of sucralfate gel and suspension in upper gastrointestinal diseases 66
Helicobacter pylori in Patients with Gastric and Nongastric Cancer 66
Effects of Dietary Fat on Postprandial Gastrointestinal Motility Are Inhibited by a Cholecystokinin Type A Receptor Antagonist 62
Helicobacter pylori, diagnosis and treatment after 10 years of its discovery 58
The susceptibility of helicobacter pylori to the rifamycin, rifaximin 58
Helicobacter pylori status, endoscopic findings, and serology in HIV-1-positive patients 53
Serological response to Helicobacter pylori in gastric and non-gastric cancer 53
Helicobacter pylori status, endoscopic findings, and serology in HIV-1-positive patients 52
The susceptibility of helicobacter pylori to the rifamycin, rifaximin 50
Spectrotypic analysis of antibodies to Helicobacter pylori in patients with antral gastritis and duodenal ulcer 49
Serological response to Helicobacter pylori in gastric and non-gastric cancer 49
Spectrotypic analysis of antibodies to Helicobacter pylori in patients with antral gastritis and duodenal ulcer 49
Helicobacter pylori, diagnosis and treatment after 10 years of its discovery 48
A clinical study of gastric emptying and bioadhesitivity of two forms of sucralfate 48
Hypersensitivity of gastric parietal cells to selective H2-receptor stimulation in duodenal ulcer 47
Endoscopic findings in 288 asymptomatic blood donors according to high levels of IgG to helicobacter pylori 45
Endoscopic findings in 288 asymptomatic blood donors according to high levels of IgG to helicobacter pylori 43
Clinical aspects of serology in the diagnosis of Helicobacter pylori infection 40
Lactose Malabsorption in Adult Patients with Crohn's Disease 39
Detection of helicobacter pylori-like organisms in the stomach of some food-source animals using a monoclonal antibody 38
Biliary surgery without the surgeon! 38
Detection of helicobacter pylori-like organisms in the stomach of some food-source animals using a monoclonal antibody 36
Source of Helicobacter pylori Infection 36
Circadian rhythm of gastric inhibitory polypeptide (GIP) in man 36
Peptic ulcer disease and Helicobacter pylori infection 34
Peptic ulcer disease and Helicobacter pylori infection 34
Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pyloni in dyspeptic patients 33
Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pyloni in dyspeptic patients 33
Optimal nutritional indexes in gastroenterology 33
Comparison of urease tests for the diagnosis of Helicobacter pylori infection 32
Clinical aspects of serology in the diagnosis of Helicobacter pylori infection 32
Comparison of urease tests for the diagnosis of Helicobacter pylori infection 30
Helicobacter pylori: its role in gastric disease 28
Helicobacter pylori and other spiral organisms in gastroduodenal disease 28
Helibacter pylori and gastroduodenal disease 26
Treatment of symptom-free Helicobacter pylori-positive subjects 26
Prevalence of peptic ulcer in Helicobacter pylori positive blood donors 24
Helicobacter pylori: its role in gastric disease 23
Helicobacter pylori and acid-related diseases of the stomach: mechanisms of pathogenesis 22
Prevalence of peptic ulcer in Helicobacter pylori positive blood donors 22
Prevalence of Helicobacter pylori in military barracks 22
Helicobacter pylori and other spiral organisms in gastroduodenal disease 22
Pathogenic mechanisms of acid-related diseases: Helicobacter and other spiral organisms 21
Biliary surgery without the surgeon! 21
Prevalence of Helicobacter pylori in military barracks 21
Helicobacter pylori and acid-related diseases of the stomach: mechanisms of pathogenesis 20
Helibacter pylori and gastroduodenal disease 20
Screening for Helicobacter pylori 19
Source of Helicobacter pylori Infection 19
Pathogenic mechanisms of acid-related diseases: Helicobacter and other spiral organisms 18
Treatment of symptom-free Helicobacter pylori-positive subjects 15
Lipid, lipoprotein, and apolipoprotein assessment during an 8-wk very-low-calorie diet 11
Totale 5.256
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.589
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.589
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022256 0 0 0 4 2 1 1 2 81 33 100 32
2022/2023525 48 76 51 28 28 37 17 39 99 19 32 51
2023/2024270 73 33 23 24 21 49 6 22 3 13 3 0
2024/20251.097 41 81 63 59 322 50 89 37 10 109 22 214
2025/20262.393 134 181 247 168 248 100 167 206 551 223 72 96
2026/2027704 85 157 235 227 0 0 0 0 0 0 0 0
Totale 5.256